TYRA

Tyra Biosciences, Inc. NASDAQ

Healthcare ·Biotechnology ·US · tyra.bio

$35.14

Mkt Cap $1.9B

52w Low $8.75 82.7% of range 52w High $40.65

50d MA $35.80 200d MA $22.83

P/E (TTM) -16.9x

EV/EBITDA -12.5x

P/B 7.8x

Debt/Equity 0.0x

ROE -46.3%

P/FCF -16.4x

RSI (14) —

ATR (14) —

Beta 0.96

50d MA $35.80

200d MA $22.83

Avg Volume 1.1M

About

Tyra Biosciences, Inc., a preclinical-stage biopharmaceutical company, focuses on developing therapies to overcome tumor resistance and enhance outcomes for patients with cancer. Its lead product candidate is TYRA-300, a selective inhibitor of fibroblast growth factor receptor (FGFR)3 for the treatment of muscle invasive bladder cancer. The company is also developing programs targeting FGFR2- intr…

Recent Earnings

Date	Time	Est	Rptd	Surp	Base	Gap%	D1%	D2%	D3%	D4%	D5%	1M%	Guide ▲★
Mar 2, 2026	AMC	-0.54	-0.57	-5.6%	32.52	-3.4%	+1.5%	+8.5%	+6.2%	+7.7%	+3.8%	+17.7%	—
Nov 5, 2025	AMC	-0.50	-0.50	+0.0%	14.82	-0.6%	-3.6%	-3.4%	-2.2%	+2.1%	+4.5%	+45.1%	—
Aug 14, 2025	AMC	-0.53	-0.47	+11.3%	10.70	+5.1%	+0.3%	+1.0%	-4.7%	-4.3%	+9.3%	+15.0%	—
May 8, 2025	AMC	-0.49	-0.47	+4.1%	10.07	-0.3%	+0.2%	+1.9%	-0.9%	-4.0%	-2.1%	+1.9%	—
Mar 27, 2025	AMC	-0.48	-0.43	+10.4%	9.66	+8.7%	+1.1%	-3.7%	-9.7%	-10.5%	-14.1%	+7.0%	—
Nov 7, 2024	AMC	-0.40	-0.41	-2.5%	17.15	-2.7%	-6.1%	-5.4%	-7.1%	-8.2%	-4.7%	-6.7%	—
Aug 7, 2024	AMC	-0.41	-0.32	+22.0%	19.50	+3.2%	+4.3%	+3.0%	+3.7%	+10.2%	+10.6%	+5.6%	—
May 9, 2024	AMC	-0.46	-0.35	+23.9%	17.76	+2.7%	-2.3%	+4.2%	+4.6%	+3.8%	+7.5%	+12.6%	—
Mar 19, 2024	AMC	-0.48	-0.53	-10.4%	16.10	+9.4%	+7.9%	+3.9%	+3.9%	+2.3%	+0.3%	-8.9%	—
Nov 7, 2023	AMC	-0.35	-0.49	-40.0%	12.16	-3.0%	-1.3%	-4.3%	-3.3%	-3.9%	+1.4%	+7.9%	—
Aug 10, 2023	AMC	-0.34	-0.31	+8.8%	15.11	+0.0%	+1.9%	+2.6%	+2.6%	-1.5%	-6.0%	-0.9%	—
May 4, 2023	AMC	-0.37	-0.28	+24.3%	12.78	+5.5%	-2.8%	+5.6%	+7.6%	+0.2%	-3.9%	+7.0%	—

Recent Analyst Ratings

Date	Firm	Action	Grade	Target	Base	Open	Gap%	D1%	D2%	D3%	D4%	D5%
Mar 20	Piper Sandler	Maintains	Overweight → Overweight	—	$38.18	$38.67	+1.3%	-2.7%	-4.3%	-4.9%	-3.9%	-0.4%
Feb 17	HC Wainwright & Co.	Maintains	Buy → Buy	—	$27.99	$28.07	+0.3%	+4.0%	+5.0%	+11.9%	+12.8%	+19.0%
Feb 13	Wedbush	Maintains	Outperform → Outperform	—	$29.19	$29.41	+0.8%	-4.1%	-0.2%	+0.7%	+7.3%	+8.2%
Feb 3	Oppenheimer	Maintains	Outperform → Outperform	—	$31.02	$31.72	+2.3%	+0.7%	-0.8%	-5.0%	-0.1%	-1.7%
Feb 3	Jefferies	Maintains	Buy → Buy	—	$31.02	$31.72	+2.3%	+0.7%	-0.8%	-5.0%	-0.1%	-1.7%
Jan 23	Piper Sandler	Maintains	Overweight → Overweight	—	$30.91	$31.51	+1.9%	-1.7%	-2.4%	+1.6%	+0.6%	+4.6%
Dec 16	Wedbush	Maintains	Outperform → Outperform	—	$22.12	$22.56	+2.0%	+3.8%	+2.2%	+3.9%	+15.3%	+14.7%
Aug 22	HC Wainwright & Co.	Maintains	Buy → Buy	—	$11.70	$11.72	+0.2%	+0.1%	+2.6%	+8.0%	+10.1%	+5.7%
Jul 1	HC Wainwright & Co.	Maintains	Buy → Buy	—	$9.57	$9.53	-0.4%	+1.6%	+5.0%	+4.5%	+0.4%	+3.6%
Mar 31	HC Wainwright & Co.	Maintains	Buy → Buy	—	$9.77	$9.48	-3.0%	-4.8%	-10.7%	-11.5%	-15.0%	-20.8%
Feb 18	HC Wainwright & Co.	Maintains	Buy → Buy	—	$13.19	$13.40	+1.6%	-4.5%	-3.0%	-3.1%	-0.2%	-2.8%
Jan 13	HC Wainwright & Co.	Maintains	Buy → Buy	—	$15.20	$15.00	-1.3%	-0.7%	+4.9%	+10.1%	+6.2%	+6.5%
Nov 11	HC Wainwright & Co.	Maintains	Buy → Buy	—	$16.11	$16.02	-0.6%	+0.7%	-1.1%	-2.3%	+1.4%	-4.5%
Oct 29	HC Wainwright & Co.	Maintains	Buy → Buy	—	$19.89	$20.28	+2.0%	-15.0%	-19.7%	-16.1%	-17.6%	-17.4%
Oct 28	HC Wainwright & Co.	Maintains	Buy → Buy	—	$21.93	$22.30	+1.7%	-9.3%	-22.9%	-27.2%	-23.9%	-25.3%
Oct 25	Wedbush	Maintains	Outperform → Outperform	—	$28.61	$23.98	-16.2%	-23.3%	-30.5%	-40.9%	-44.2%	-41.7%
Oct 18	BofA Securities	Upgrade	Neutral → Buy	—	$25.98	$27.00	+3.9%	+5.2%	+9.2%	+8.4%	+8.7%	+10.1%
Oct 7	HC Wainwright & Co.	Maintains	Buy → Buy	—	$22.04	$22.19	+0.7%	-5.4%	-1.8%	-3.4%	-4.8%	-0.5%
Sep 19	Oppenheimer	Maintains	Outperform → Outperform	—	$23.20	$24.00	+3.4%	+3.4%	+5.0%	+1.9%	+2.0%	+0.3%
Aug 8	Oppenheimer	Maintains	Outperform → Outperform	—	$19.50	$20.12	+3.2%	+4.3%	+3.0%	+3.7%	+10.2%	+10.6%
Aug 8	Wedbush	Maintains	Outperform → Outperform	—	$19.50	$20.12	+3.2%	+4.3%	+3.0%	+3.7%	+10.2%	+10.6%
Jul 3	Wedbush	Maintains	Outperform → Outperform	—	$16.70	$16.83	+0.8%	+1.6%	+2.4%	+6.5%	+9.0%	+8.4%
Jul 3	Oppenheimer	Maintains	Outperform → Outperform	—	$16.70	$16.83	+0.8%	+1.6%	+2.4%	+6.5%	+9.0%	+8.4%
Jul 3	HC Wainwright & Co.	Maintains	Buy → Buy	—	$16.70	$16.83	+0.8%	+1.6%	+2.4%	+6.5%	+9.0%	+8.4%
Jun 5	HC Wainwright & Co.	Maintains	Buy → Buy	—	$17.75	$17.97	+1.2%	+7.2%	+11.5%	+11.4%	+12.7%	+13.9%
May 13	Oppenheimer	Maintains	Outperform → Outperform	—	$17.35	$17.61	+1.5%	+6.6%	+7.1%	+6.3%	+10.1%	+5.2%
May 10	Wedbush	Maintains	Outperform → Outperform	—	$17.76	$18.24	+2.7%	-2.3%	+4.2%	+4.6%	+3.8%	+7.5%
May 10	HC Wainwright & Co.	Maintains	Buy → Buy	—	$17.76	$18.24	+2.7%	-2.3%	+4.2%	+4.6%	+3.8%	+7.5%
Mar 21	Wedbush	Maintains	Outperform → Outperform	—	$17.37	$17.45	+0.5%	-3.7%	-3.7%	-5.2%	-7.0%	-6.2%
Mar 20	HC Wainwright & Co.	Maintains	Buy → Buy	—	$16.10	$17.61	+9.4%	+7.9%	+3.9%	+3.9%	+2.3%	+0.3%
Dec 29	Wedbush	Maintains	Outperform → Outperform	—	$13.90	$14.58	+4.9%	-0.4%	+1.0%	-9.0%	-12.6%	-16.5%
Dec 26	HC Wainwright & Co.	Maintains	Buy → Buy	—	$13.45	$13.96	+3.8%	+8.3%	+4.1%	+3.3%	+3.0%	+4.4%
Nov 8	HC Wainwright & Co.	Maintains	Buy → Buy	—	$12.16	$11.80	-3.0%	-1.3%	-4.3%	-3.3%	-3.9%	+1.4%
Aug 11	HC Wainwright & Co.	Maintains	Buy → Buy	—	$15.11	$15.11	+0.0%	+1.9%	+2.6%	+2.6%	-1.5%	-6.0%
Aug 11	Wedbush	Maintains	Outperform → Outperform	—	$15.11	$15.11	+0.0%	+1.9%	+2.6%	+2.6%	-1.5%	-6.0%
Aug 1	HC Wainwright & Co.	Maintains	Buy → Buy	—	$14.82	$14.81	-0.1%	-2.8%	-1.5%	-0.1%	-3.4%	-5.5%
May 8	Oppenheimer	Maintains	Outperform → Outperform	—	$12.42	$12.14	-2.3%	+8.7%	+10.7%	+3.1%	-1.1%	-0.2%
May 5	HC Wainwright & Co.	Maintains	Buy → Buy	—	$12.78	$13.48	+5.5%	-2.8%	+5.6%	+7.6%	+0.2%	-3.9%
Mar 23	HC Wainwright & Co.	Maintains	Buy → Buy	—	$15.17	$15.50	+2.2%	+1.8%	+5.1%	+5.3%	+5.1%	+6.9%
Mar 7	HC Wainwright & Co.	Maintains	Buy → Buy	—	$13.60	$14.36	+5.6%	+10.3%	+11.6%	+11.0%	-11.2%	-4.3%
Mar 2	HC Wainwright & Co.	Maintains	Buy → Buy	—	$12.77	$13.11	+2.7%	-4.3%	-5.0%	+6.5%	+17.5%	+18.9%
Feb 3	Oppenheimer	Maintains	Outperform → Outperform	—	$13.30	$13.75	+3.4%	-0.9%	+1.1%	+1.7%	-1.7%	+5.6%
Jun 23	HC Wainwright & Co.	Maintains	Buy → Buy	—	$6.27	$6.88	+9.7%	+11.3%	+14.0%	+4.6%	+15.9%	+29.7%
Mar 8	Jefferies	Upgrade	Hold → Buy	—	$10.96	$11.93	+8.9%	+3.3%	+10.3%	+2.0%	+0.3%	-3.6%
Nov 8	Jefferies	Downgrade	Buy → Hold	—	$28.39	$28.95	+2.0%	+2.3%	-0.7%	-2.3%	-0.6%	-2.9%
Oct 11	Jefferies	Maintains	Buy → Buy	—	$16.26	$15.95	-1.9%	-5.3%	-3.7%	+0.7%	+0.1%	+0.5%
Oct 11	BofA Securities	Maintains	Buy → Buy	—	$16.26	$15.95	-1.9%	-5.3%	-3.7%	+0.7%	+0.1%	+0.5%
Oct 11	Cowen & Co.	Maintains	Outperform → Outperform	—	$16.26	$15.95	-1.9%	-5.3%	-3.7%	+0.7%	+0.1%	+0.5%

Recent Filings

8-K

Tyra Biosciences, Inc. -- 8-K Filing

Tyra Biosciences appointed a board member with significant biopharmaceutical experience, including prior roles at Blueprint Medicines (acquired by Sanofi) and other therapeutic companies.

Apr 17

8-K

Unknown — 8-K Filing

I cannot provide a meaningful analysis because the filing content is incomplete metadata/technical specifications rather than substantive financial information about State Street (STT) or Tyra Biosciences (TYRA).

Apr 2

8-K

Tyra Biosciences, Inc. -- 8-K Filing

I cannot provide a meaningful one-sentence analysis because the summary contains only technical XBRL metadata and filing administrative information rather than substantive business news or events affecting Tyra Biosciences investors.

Mar 4

8-K

Tyra Biosciences, Inc. -- 8-K Filing

Tyra Biosciences reported 2025 year-end financial results and corporate progress updates for its FGFR-focused precision medicine pipeline, with CEO Todd Harris emphasizing the company's science-driven development strategy.

Mar 2

Data updated apr 27, 2026 6:20am · Source: massive.com